Revised SPC: Zirabev (bevacizumab) 25 mg/ml concentrate for solution for infusion

SPCs revised to include license extension for use in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin for treatment of adults with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer under specific conditions.

Source:

electronic Medicines compendium